



## **IT à distance de la chirurgie mitrale : quand intervenir ?**

**Jean-François OBADIA**




**Cardiothoracique Surgery and Transplantation  
Hôpital Louis Pradel  
- Lyon - France -**



***About 100 Pts → Mortality 14%***

***“tricuspid regurgitation will improve or disappear after mitral replacement and tricuspid valve replacement is seldom necessary”***



**Tricuspid → The forgotten valve  
Orphan disease**




## Tricuspid valvectomy following tricuspid valve endocarditis on an intravenous drug addict

P. NIHOYANNOPOULOS

50 years old male  
drug abuser



Survival > 10 years






## Tricuspid Regurgitation: Clinical Importance and Its Optimal Surgical Timing Kim HK. Seoul Korea.

### Pubmed 1900 to 2012

- mitral regurgitation  
    ➔ 24013 papers
- tricuspid regurgitation  
    ➔ 4294 papers



Late significant TR (-)

245    242    238    226    219    217    217

Late significant TR (+)

90    88    85    81    78    70    69

# Incidence of Valve diseases



## Estimated structural heart valve disease (USA)

Valve lesion *	Population	Currently treated
Mitral regurgitation	2,520,000	48,000 (2%)
Aortic stenosis	749,000	79,000 (10%)
Tricuspid regurgitation	1,600,000	< 8,000

“The Forgotten Valve”

\* Moderate to severe & severe valvular lesions

**Less than 0.5% of cases**



- **70% of Normal Subjects Have Trivial TR**
- **90% of Cardiac Patients Have TR**

Stuge O. et al. JTCS 2006;132:1258-61



## Tricuspid Regurgitation depends on:

- Tricuspid Diameter
- Preload: Blood Volume
- RV Function
- Afterload (the only factor corrected by mitral repair): PVR



# Impact on the follow-up




1967 → 2004



**Circulation. 1967; 35: 1-63-1-69**

**100 Pts**

**No impact after Mitral valve surg**



**5223 consecutive echo  
Veterans Affairs Health Care Syst  
August 1998 and July 2002.**

**JACC 2004;43:405-9**


**5223 pts  
independent of age, EF, PAP**



188 TV replacements





- reoperations 48.1%

- associated procedures 71.3%





**N = 54375 pts**  
**Concomitant Procedure = 86%**  
**Repair = 89 % (75% ring)**





## MANAGEMENT OF TRICUSPID VALVE REGURGITATION

Manuel J Antunes, John B Barlow. Heart 2007;93:271-276

- 1) Hospital mortality for repeat tricuspid valve surgery may reach 50%.  
→ Surgery should, therefore, be delayed.
- 2) High functional class, severe right heart failure, low right ventricular ejection fraction, high pulmonary pressure and pulmonary arterial resistance are additional risk factors when repeating tricuspid surgery.  
→ Surgery should be done early



TR repair should be prophylactic associated with the left side surgery

**IT à distance de la chirurgie mitrale : quand intervenir ?**  
**Jamais !!!**

## Secondary TR or dilatation ?

« *Dreyfus G et al. Ann Thorac Surg 2005 ; 79 : 127-32* »





<b><u>311 MV Repair</u></b> <b>Annulus&gt;70mm</b>	<b>163 MVR</b> <b>no</b>	<b>148 MVR + Tric</b> <b>yes</b>
<b>Mortality</b>	<b>1,8 %</b>	<b>0,7 %</b>
<b>Survival 3 years</b>	<b>97 %</b>	<b>98 %</b>
<b>10 years</b>	<b>85 %</b>	<b>90 %</b>
<b>NYHA</b>	<b>1,59</b>	<b>1,11</b>
<b>TR recurrence</b>	<b>48 %</b>	<b>2 %</b>
<b>Pace Maker</b>	<b>3,1 %</b>	<b>5,4 %</b>



- 1) *Considerable tricuspid dilatation present in the absence of substantial TR.*
- 2) *Annuloplasty based on dilation improvement irrespective of the TI grade*

# Secondary TR or dilatation ?

« *Dreyfus G et al. Ann Thorac Surg 2005 ; 79 : 127-32* »




*Courtesy of A Berrebi*



- 1) *Considerable tricuspid dilatation present in the absence of substantial TR.*
- 2) *Annuloplasty based on dilation improvement irrespective of the TI grade*



## Mitral Valve Repair > 20 years TR = 11 %



**Figure 1.** Rates at 10 and 20 years for freedom from cardiac death, expected survival, and overall survival.


« *Braunberger Circulation 2001* »



# PACEMAKERS and TRICUSPID

**Pacemaker Therapy After Tricuspid Valve Operations: Implications on Mortality, Morbidity, and Quality of Life.** Janne J. Jokinen et al.  
*Ann Thorac Surg* 2009;87:1806-1814


**28 / 136 Pts 8 years**  
- *11% before discharge*  
- *10% after*





# Impact of the Maze Operation With Left-Sided Valve Surgery on the Change in TR over Time



Kim HK, Circulation 2005 ; 112(9 suppl):I-14-I-19



A: Preoperative examination  
B: Immediate postoperative examination  
C: Last examination




The maze operation reduces the risk of late significant TR by as much as 79%




**82 Isolated TV Repair/Replac**

MIS → 60%  
Ao Clamping → 20%





**Post-operative :**

- + Overall → 14.6%
- + Elective → 4 %
- + MIS → 0%
- Low CI → 15%
- PM → 8.5%













**117 TV Replacement (94.9% Bioprostheses)**  
**52% Isolated TVR → 85% Right T / beating Heart**



**Table 4:** Preoperative predictors of 30-day mortality

117 patients	Alive (n = 110)	Dead (n = 7)	P-value	OR (95% CI)
Age mean, years	62.8 ± 9.7	58.4 ± 10.9	0.255	0.96 (0.89–1.03)
LES median, %	11.6 (8.1–16.0)	38.7 (13.3–45.9)	0.002*	1.16 (1.06–1.27)
Ascites	35 (31.9%)	6 (85.7%)	0.004*	12.86 (1.49–110.89)
Number of previous operations >1	30 (27.3%)	4 (57.1%)	0.091	3.56 (0.75–16.83)
I-TVR	56 (50.9%)	5 (71.4%)	0.292	2.41 (0.45–12.96)
LVEF mean, %	54.9 ± 8.5	46.2 ± 11.8	0.072	0.92 (0.84–1.01)
RV dysfunction ≥ moderate	24 (21.8%)	4 (57.1%)	0.033*	4.78 (1.00–22.82)
sPAP mean, mmHg	47.5 ± 12.9	63.7 ± 24.9	0.046*	1.05 (1.00–1.11)



# Surgical Techniques



Rigid or flexible annular bands

Suture bicuspidalization

# Edge to Edge « *Clover Shape* »



*De Bonis. Ann Thor Surg 2004;81:2179-82*



## RV Assistance





## Mini-Invasive Approaches



# Percutaneous Approach



## TriCinch™ (4TECH Cardio Ltd, Ireland)





**Table 16** Indications for tricuspid valve surgery

	Class <sup>a</sup>	Level <sup>b</sup>
Surgery is indicated in symptomatic patients with severe TS. <sup>c</sup>	I	C
Surgery is indicated in patients with severe TS undergoing left-sided valve intervention. <sup>d</sup>	I	C
Surgery is indicated in patients with severe primary or secondary TR undergoing left-sided valve surgery.	I	C
Surgery is indicated in symptomatic patients with severe isolated primary TR without severe right ventricular dysfunction.	I	C
Surgery should be considered in patients with moderate primary TR undergoing left-sided valve surgery.	IIa	C
Surgery should be considered in patients with mild or moderate secondary TR with dilated annulus ( $\geq 40$ mm or $> 21$ mm/m <sup>2</sup> ) undergoing left-sided valve surgery.	IIa	C
Surgery should be considered in asymptomatic or mildly symptomatic patients with severe isolated primary TR and progressive right ventricular dilatation or deterioration of right ventricular function.	IIa	C
After left-sided valve surgery, surgery should be considered in patients with severe TR who are symptomatic or have progressive right ventricular dilatation/dysfunction, <i>in the absence</i> of left-sided valve dysfunction, severe right or left ventricular dysfunction, and severe pulmonary vascular disease.	IIa	C

**Severe symptomatic TR  
RV dilatation  
no L or R Vent. dysfunction  
no severe PHT**

**IT à distance : quand intervenir ?**

**Jamais !!!**



**Seule réponse = Anticiper**



## IT à distance de la chirurgie mitrale : quand intervenir ?



### ANTICIPATION :

#### -Ring if Ann > 40mm

- . *Rhum ≠ Dystrophic*
- . *30% Recurrent TR*

#### - AF ablation

### Never too Early



### Never too late



Percutaneous